FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

## Washington, D.C. 20049

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  GURY DAVID J		2. Issuer Name <b>and</b> Ticker or Trading Symbol NABI BIOPHARMACEUTICAL				<u>S</u> [ NA	BI ]	5. Relationship of Repor (Check all applicable) X Director		olicable) ctor	100	% Owner		
(Last) (First) (Middle) C/O NABI BIOPHARMACEUTICALS 5800 PARK OF COMMERCE BOULEVARI		11/13/2003				saction (Month/Day/Year)					Offic belov	er (give title w)		er (specify ow)
(Street) BOCA RATON FL 33487		4. If A	amendment, Da	ate of Or	igina	al File	d (Month/Da	y/Year)		6. Inc Line)	Forn	n filed by Or	up Filing (Checone Reporting Fore than One F	erson
(City) (State) (Zip)														
Table I - Non-Derivat  1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day/Y			ion 2A. Deemed Execution Date,			3. 4. Securities Disposed Of Code (Instr. 5)			of, or Beneficial les Acquired (A) or Of (D) (Instr. 3, 4 and			ed int of es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
				Co	de	v	Amount	(A) or (D)	Price	•	Transaction(s) (Instr. 3 and 4)			<u> </u>
Common Stock	11/13/20	03		S			5,422	D	\$10		538,1	58.5813	D	
Common Stock	11/13/2003			S			4,000	D	\$10		534,158.5813		D	
Common Stock	11/14/20			S	-		4,000	D	\$10			58.5813	D	
Common Stock	11/14/20	03		S			2,000	D	\$1	1.1	528,1	58.5813	D	
Common Stock	11/14/20	03		s			3,000	D	\$11	.14	110	,400 <sup>(1)</sup>	I	By immediate family
Common Stock	11/14/20	03		S			2,000	D	\$11	.17	108	,400 <sup>(1)</sup>	I	By immediate family
Common Stock	11/14/20	03		S			2,000	D	\$1	1.2	106	,400(1)	I	By immediate family
Common Stock										1,500		500(1)	I	By trust for benefit of children
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)														
1. Title of Derivative Conversion Date 3A. Deemed Execution Date,		5. Number of Operivative		er 6. D Exp (Mo es d	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price Derivat Securit (Instr. 5		derivative Securities	Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership ot (Instr. 4)	
	Co	ode \	V (A) (C	Date D) Exe	e rcisa	able	Expiration Date		Amoun or Numbe of Shares					

## **Explanation of Responses:**

1. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

## Remarks:

/s/ James E. Dawson, as attorney-in-fact

11/17/2003

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

 $<sup>^{\</sup>star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

<sup>\*\*</sup> Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.